Novartis AG ADR logo

Novartis AG ADR(NVS)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
3-STAR RATING
STRONG BUY
BUY for 18 days
PROFIT SINCE LAST BUY
+2.51% ▲
LAST CLOSE
$160.2
11/16/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for NVS

11/16/2026: NVS (3-star) is a STRONG-BUY. BUY for 18 days. Simulated Profits (2.51%). Updated daily EoD!

Novartis AG is a global biopharmaceutical company focusing on innovative prescription medicines across oncology, immunology, neuroscience, and cardiovascular care. The company benefits from a solid portfolio of specialty blockbusters, strong profit margins, and a disciplined focus on high-margin therapeutics following the spin-off of its generic division. Its primary growth story is anchored by pipeline expansion in advanced modalities like radioligand and gene therapies. However, key risks include patent expirations on legacy blockbusters and intense pricing pressures. The stock is well-suited for dividend and low-risk healthcare investors seeking stable exposure, though market participants should closely monitor pipeline execution and regulatory developments.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitNovartis offers steady medium-term growth driven by innovative drug rollouts, but lacks hyper-growth tech characteristics.
Momentum investorStrong fit while signal remains positiveMomentum fit is conditional on positive clinical trial updates, regulatory approvals, and upward earnings revisions.
Value investorMixed fitValuation is generally in line with large-cap pharmaceutical peers, offering reasonable metrics without deep discount margins.
Dividend investorStrong fitThe company offers a reliable dividend yield supported by defensive cash flows and a stable payout history.
Low-risk investorStrong fitAs a large-cap healthcare company with defensive characteristics, it exhibits lower structural volatility than cyclical equities.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityLowLarge-cap pharmaceutical stocks tend to trade with lower volatility relative to broader equity markets.
Valuation riskMediumValuations can compress if key drug launches underperform or pricing pressures accelerate.
Competition risk (patent and generic competition theme)HighThe expiration of patent protection on major blockbusters exposes revenues to rapid generic erosion.
Business qualityStrongNovartis possesses an established global footprint, deep R&D capabilities, and strong operational infrastructure.
Dividend incomeMedium / highIncome investors benefit from consistent payouts backed by stable pharmaceutical demand.
Execution riskMediumSuccess depends heavily on clinical trial outcomes, regulatory approvals, and successful commercial scaling.

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 303.12B USD
Price to earnings Ratio 30.63
1Y Target Price 157.1
Price to earnings Ratio 30.63
1Y Target Price 157.1
Volume (30-day avg) 2.0M shares
Beta 0.45
52 Weeks Range 119.60 - 165.96
Updated Date 11/15/2026
52 Weeks Range 119.60 - 165.96
Updated Date 11/15/2026
Dividends yield (FY) 2.95%
Basic EPS (TTM) 5.24

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
63.9%
Active BUY / eligible
69 / 108
30-Day BUY Count Change
+31
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Drug Manufacturers - General

BUY participation
77.8%
Active BUY / eligible
7 / 9
30-Day BUY Count Change
+4

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Flat / Range-Bound
PRICE PATH

Flat / Range-Bound

The stock price has been trading within a narrow range with minimal directional movement.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit 28.28%
Avg. Invested days 58
Today’s Advisory Strong Buy
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 4.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/16/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
NVS receives a 4-star rating, supported by strong unit economics, solid company fundamentals, and solid quantitative characteristics. The rating is constrained by weak price momentum, and limited analyst upside.

Company Fundamentals

★★★★★
NVS has solid overall fundamentals (4 stars), with solid financial health, solid growth momentum, and moderate ownership. In FY2025 versus FY2024, solid earnings growth (+17.1%) and strong cash generation (FCF margin 31.0%) are partially offset by moderate revenue growth (+9.6%), very low insider ownership of 0.02%.

Financial Health Rating

★★★★★
NVS's financial health is supported by strong cash strength, including free-cash-flow generation of $17.6B (31.0% of revenue). Liquidity is solid (4 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is NVS's strongest growth driver at +27.5% FY2025 versus FY2024 (solid, 4 stars). Revenue growth (+9.6%, moderate) and earnings growth (+17.1%, solid) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 7.1% (soft) and 97.7% of outstanding shares are publicly tradable (strong). Insider ownership is only 0.02%, which materially reduces the ownership score.

Top 5 Institutional Investors

Fisher Asset Management, LLC 0.82%
Morgan Stanley - Brokerage Accounts 0.46%
Dimensional Fund Advisors, Inc. 0.42%
PRIMECAP Management Company 0.35%
Loomis, Sayles & Company LP 0.28%

Unit Economics (Per $1K Revenue)

★★★★★
NVS generates approximately $758 of gross profit, $311 of operating income, and $310 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Strong margins, cash conversion, and capital efficiency support the rating.

Economic Dimensions

★★★★★
Effective Tax Rate: 14.59%

Quantitative Style Profile

★★★★★
NVS has a high-quality, large-cap, liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Quality TiltLow VolatilityLarge / Mega Cap StabilityHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Innovative Medicines (Global Commercial Sales)Revenues generated from patented prescription drugs across oncology, immunology, neuroscience, and cardiovascular markets.This is the core engine of Novartis, where high-margin drugs drive the bulk of profits.
Geographic FootprintMajor sales distributed across the United States, Europe, and emerging markets like China.Geographic diversification helps insulate the company from localized healthcare policy and pricing shifts.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-10-27
When Before Market
Estimate 2.25
Actual 2.46

Profitability

Profit Margin 17.49%
Operating Margin (TTM) 33.98%

Management Effectiveness

Return on Assets (TTM) 10.86%
Return on Equity (TTM) 24.33%

Valuation

Trailing PE 30.63
Forward PE 16.03
Enterprise Value 342.17B
Price to Sales(TTM) 5.28
Enterprise Value 342.17B
Price to Sales(TTM) 5.28
Enterprise Value to Revenue 5.96
Enterprise Value to EBITDA 15.57
Shares Outstanding 1.89B
Shares Floating 1.84B
Shares Outstanding 1.89B
Shares Floating 1.84B
Percent Insiders 0.02
Percent Institutions 7.09

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.